SCHEMBL3267640

SCHEMBL3267640

CCC=Cc1ccc2ccccc2c1C=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
GAA P10253 2/20 0.49
ERN1 O75460 2/20 0.49
MAPT P10636 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SMPD2 O60906 1/20 0.36
POLB P06746 2/20 0.35
PTPN1 P18031 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 2/20 0.34
CYP2A6 P11509 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267637 1.00 L3MBTL1 (0.49) L3MBTL1TDP1GAAERN1MAPT
SCHEMBL3273913 0.81 ERN1 (0.53) L3MBTL1TDP1GAAERN1MAPT
SCHEMBL3273911 0.81 ERN1 (0.53) L3MBTL1TDP1GAAERN1MAPT
SCHEMBL197337 0.79 ERN1 (0.62) L3MBTL1TDP1GAAERN1MAPT
SCHEMBL31663413 0.79 ERN1 (0.62) L3MBTL1TDP1GAAERN1MAPT
SCHEMBL3267319 0.77 MAOB (0.48) TDP1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3267323 0.77 MAOB (0.48) TDP1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL8210032 0.77 ERN1 (0.51) L3MBTL1TDP1GAAERN1MAPT
SCHEMBL615456 0.75 SMPD2 (0.51) SMPD2MTNR1AMTNR1B
SCHEMBL615455 0.75 SMPD2 (0.51) SMPD2MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1914229-B1 NOVEL CERCOSPORAMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-06-16 EP disclosed
US-20090036492-A1 Novel Cercosporamide Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-02-05 US disclosed
EP-1914229-A1 NOVEL CERCOSPORAMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036492-A1 Novel Cercosporamide Derivative GPR119, CBR3, SLC5A2 L3MBTL1 863/4885TDP1 4587/4885GAA 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.